[Esophageal candidiasis during interferon therapy for chronic viral hepatitis C].
Prignet
J M
JM
Galzin
M
M
Demarquay
J F
JF
Raynard
B
B
Louvety
S
S
Künkel
D
D
D002177:Candidiasis / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology; D004935:Esophageal Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006526:Hepatitis C / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015725:Fluconazole
Candidose oesophagienne au cours d'un traitement par l'interféron d'une hépatite chronique à virus C.